Celldex Therapeutics
CLDX
168 hedge funds and large institutions have $1.65B invested in Celldex Therapeutics in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 64 increasing their positions, 52 reducing their positions, and 30 closing their positions.
85% more call options, than puts
Call options by funds: $72.7M | Put options by funds: $39.3M
23% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 52
6.88% more ownership
Funds ownership: 98.77% → 105.65% (+6.9%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
6% less capital invested
Capital invested by funds: $1.75B → $1.65B (-$104M)
7% less funds holding
Funds holding: 180 → 168 (-12)
33% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$43M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$34.8M |
| 3 |
Morgan Stanley
New York
|
+$22.8M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$16.8M |
| 5 |
TLP
Tri Locum Partners
New York
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$26.8M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$20.7M |
| 3 |
CAC
Cowen and Company
New York
|
-$18M |
| 4 |
FAM
Fred Alger Management
New York
|
-$11.1M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$10.5M |
CLDX Hedge Fund Activity: Q1 2022 in Review
168 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2022, worth a combined $1.65B — down 5.9% from $1.75B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of CLDX and 20 opened new positions — a net loss of 10 holders — while 52 trimmed existing stakes and 64 added.
The largest buyer was Wellington Management Group, adding an estimated $43M. The largest seller was RTW Investments, cutting an estimated $26.8M.
- 168 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2022, down from 180 in Q4 2021.
- Funds reported $1.65B of Celldex Therapeutics stock for Q1 2022, down 5.9% quarter-over-quarter.
- 20 funds opened new Celldex Therapeutics positions in Q1 2022 and 30 closed out, a net change of -10 holders.
- The largest Celldex Therapeutics buyer in Q1 2022 was Wellington Management Group, an estimated $43M added.
- The largest Celldex Therapeutics seller in Q1 2022 was RTW Investments, an estimated $26.8M sold.
Based on aggregated 13F filings for Q1 2022.